Trade names Toviaz MedlinePlus a609021 | AHFS/Drugs.com Monograph Routes of
administration Oral | |
 | ||
License data EU EMA: Toviaz
US FDA: Fesoterodine Pregnancy
category US: C (Risk not ruled out) | ||
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.
Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.
Efficacy
Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.
References
Fesoterodine Wikipedia(Text) CC BY-SA